Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2024

Российское кардиологическое общество

При участии: Ассоциации сердечно-сосудистых хирургов России, Российского общества скорой медицинской помощи, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению

Одобрено Научно-практическим Советом Минздрава Российской Федерации.

1. Howick JH. The Philosophy of Evidence-based Medicine. Wiley. p. 15. ISBN: 978-1-44434266-6.

2. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-2.

3. Byrne RA, Rossello X, Coughlan JJ, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38): 3720-826. doi:10.1093/eurheartj/ehad191.

4. Андреева Н. С., Реброва О. Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.

5. Thygesen K, Alpert JS, Jaffe AS, et al.; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237-69.

6. Vaduganathan M, Mensah GA, Turco JV, et al. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022;80(25):2361-71. doi:10.1016/j.jacc.2022.11.005.

7. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med. 2011;124(1):40-7.

8. CORD-3 registry workteam. Twelve months outcomes in patients with acute coronary syndrome, by the national registry RECORD-3. Russian Journal of Cardiology. 2018;(3):23-30. (In Russ.) Эрлих А. Д. от имени всех участников регистра РЕКОРД-3. 12-месячные исходы у пациентов с острым коронарным синдромом, включённых в российский регистр рекорд-3. Российский кардиологический журнал. 2018;(3):23-30. doi:10.15829/1560-4071-2018-3-23-30.

9. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31(22):2755-64. doi:10.1093/eurheartj/ehq326.

10. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163-70. doi:10.1093/eurheartj/ehu505.

11. Jollis JG. The role of national registries. Eur Heart J. 2015;36(19):1155-6. doi:10.1093/eurheartj/ehv048.

12. Amsterdam EA, Wenger N, Brindis RG, et al. 2014 AHA/ACC Guidelines for the management of patients with non-ST-elevation acute coronary syndrome: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2014;130:e344-e426.

13. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/ SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053.

14. Kontos MC, de Lemos JA, Deitelzweig SB, et al. 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(20):1925-60. doi:10.1016/j.jacc.2022. 08.750.

15. Reichlin T, Twerenbold R, Reiter M, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med. 2012;125:1205-13.

16. Сhapman AR, Lee KK, McAllister DA, et al. Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. JAMA. 2017;318:1913-24.

17. Mueller C, Giannitsis E, Mockel M, et al., Biomarker Study Group of the ESC ACCA. Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. Eur Heart J Acute Cardiovasc Care. 2017;6:218-22.

18. Pickering JW, Than MP, Cullen L, et al. Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis. Ann Intern Med. 2017;166:715-3724.

19. Miller-Hodges E, Anand A, Shah ASV, et al. High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients With Renal Impairment Presenting With Suspected Acute Coronary Syndrome. Circulation. 2018;137:425-35.

20. Camaro C, Aarts, GWA, Abang EMM, et al. Rule-out of non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin measurement: a randomized trial. European Heart Journal. 2023;44(19):1705-14. doi:10.1093/eurheartj/ehad056.

21. Giannitsis E, Becker M, Kurz K, et al. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clinical chemistry. 2010;56:642-50.

22. Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011;124:136-45.

23. Shah ASV, Anand A, Strachan FE. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018;392:919-28.

24. Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med. 2012;172:1211-8.

25. Reichlin T, Twerenbold R, Maushart C, et al. Risk stratification in patients with unstable angina using absolute serial changes of 3 high-sensitive troponin assays. Am Heart J. 2013;165:371-8.

26. Shah AS, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386: 2481-8.

27. Nestelberger T, Wildi K, Boeddinghaus J, et al. Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0h/1h-algorithm for the early diagnosis of acute myocardial infarction. Int J Cardiol. 2016;207:238-45.

28. Neumann JT, Sorensen NA, Schwemer T, et al. Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. JAMA Cardiol. 2016;1:397-404.

29. Boeddinghaus J, Reichlin T, Cullen L, et al. Two-Hour Algorithm for Triage toward Rule-Out and Rule-In of Acute Myocardial Infarction by Use of High-Sensitivity Cardiac Troponin I. Clin Chem. 2016;62:494-504.

30. Mueller C, Giannitsis E, Christ M, et al., Investigators T-A. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016;68:76-87.

31. Chapman AR, Anand A, Boeddinghaus J, et al. Comparison of the efficacy and safety of early rule-out pathways for acute myocardial infarction. Circulation. 2017;135:1586-96.

32. Boeddinghaus J, Nestelberger T, Twerenbold R, et al. Direct comparison of 4 very early rule-out strategies for acute myocardial infarction using high-sensitivity cardiac troponin I. Circulation. 2017;135:1597-611.

33. Wildi K, Cullen L, Twerenbold R, et al. Direct Comparison of 2 Rule-Out Strategies for Acute Myocardial Infarction: 2-h Accelerated Diagnostic Protocol vs 2-h Algorithm. Clin Chem. 2017;63:1227-36.

34. Boeddinghaus J, Nestelberger T, Twerenbold R, et al., Investigators T-A. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. Eur Heart J. 2018;39:3780-94.

35. Boeddinghaus J, Twerenbold R, Nestelberger T, et al., Investigators A. Clinical Validation of a Novel High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial Infarction. Clin Chem. 2018;64:1347-60.

36. Twerenbold R, Badertscher P, Boeddinghaus J, et al. 0/1-Hour Triage Algorithm for Myocardial Infarction in Patients With Renal Dysfunction. Circulation. 2018;137:436-51.

37. Twerenbold R, Neumann JT, Sorensen NA, et al. Prospective Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction. J Am Coll Cardiol. 2018;72:620-32.

38. Greenslade J, Cho E, Van Hise C, et al. Evaluating Rapid Rule-out of Acute Myocardial Infarction Using a High-Sensitivity Cardiac Troponin I Assay at Presentation. Clin Chem. 2018;64:820-9.

39. Neumann JT, Twerenbold R, Ojeda F, et al. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019;380:2529-40.

40. Neumann JT, Sorensen NA, Rubsamen N, et al. Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myocardial infarction. Int J Cardiol. 2019;283: 35-40.

41. Chapman AR, Fujisawa T, Lee KK, et al. Novel high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syndrome. Heart. 2019;105:616-22.

42. Wildi K, Nelles B, Twerenbold R, et al. Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. Am Heart J. 2016;181:16-25.

43. Badertscher P, Boeddinghaus J, Twerenbold R, et al.; for the APACE Investigators. Direct Comparison of the 0/1h and 0/3h Algorithms for Early Rule-Out of Acute Myocardial Infarction. Circulation. 2018;137:2536-8.

44. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome [published correction appears in Am Heart J. 2007;154(5):851]. Am Heart J. 2007;153(1):29-35. doi:10.1016/j.ahj.2006.10.004.

45. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segmentelevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119:1873-82.

46. Бражник В. А., Минушкина Л. О., Гулиев Р. Р. и др. Факторы риска кровотечений у больных с острым коронарным синдромом: данные наблюдательного исследования ОРАКУЛ II. Российский кардиологический журнал. 2019;24(3):7-16. doi:10.15829/1560-4071-2019-3-7-16.

47. Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013;165:918-25.

48. Hao Y, Lu Q, Li T, et al. Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention. BMC Cardiovascular Disorders. 2017;17:6.

49. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyperand hypoglycaemia and 2-year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26:1255-61.

50. Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020;41(45):4317.

51. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111-88.

52. Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307(2):157-64. doi:10.1001/jama.2011.1967.

53. Shirakabe A, Hata N, Kobayashi N, et al. Clinical significance of acid-base balance in an emergency setting in patients with acute heart failure. J Cardiol. 2012;60(4):288-94. doi:10.1016/j.jjcc.2012.06.004.

54. Maciejewski P, Bednarz B, Chamiec T, et al. Acute coronary syndrome: potassium, magnesium and cardiac arrhythmia. Kardiol Pol. 2003;59(11):402-7.

55. Babes EE, Zaha DC, Tit DM, et al. Value of Hematological and Coagulation Parameters as Prognostic Factors in Acute Coronary Syndromes. Diagnostics (Basel). 2021;11(5):850. doi:10.3390/diagnostics11050850.

56. Su H, Cao Y, Chen Q, et al. The association between fibrinogen levels and severity of coronary artery disease and long-term prognosis following percutaneous coronary intervention in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1287855. doi:10.3389/fendo.2023.1287855.

57. Shi Y, Wu Y, Bian C, et al. Predictive value of plasma fibrinogen levels in patients admitted for acute coronary syndrome. Tex Heart Inst J. 2010;37(2):178-83.

58. Perelló R, Calvo M, Miró O, et al. Clinical presentation of acute coronary syndrome in HIV infected adults: a retrospective analysis of a prospectively collected cohort. Eur J Intern Med. 2011;22(5):485-8. doi:10.1016/j.ejim.2011.02.017.

59. Seecheran VK, Giddings SL, Seecheran NA. Acute coronary syndromes in patients with HIV. Coron Artery Dis. 2017;28(2):166-72. doi:10.1097/MCA.0000000000000450.

60. Žvirblytė R, Ereminienė E, Montvilaitė A, et al. Syphilitic coronary artery ostial stenosis resulting in acute myocardial infarction. Medicina (Kaunas). 2017;53(3):211-6. doi:10.1016/j.medici.2017.06.001.

61. Fu Y, Chen M, Sun H, et al. Blood group A: a risk factor for heart rupture after acute myocardial infarction. BMC Cardiovasc Disord. 2020;20(1):471. doi:10.1186/s12872020-01756-y.

62. Scudiero F, Valenti R, Marcucci R, et al. Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. J Am Heart Assoc. 2020;9(18):e016441. doi:10.1161/JAHA.120.016441.

63. Kuo PL, Lin KC, Tang PL, et al. Contribution of Hepatitis B to Long-Term Outcome Among Patients With Acute Myocardial Infarction: A Nationwide Study. Medicine (Baltimore). 2016;95(5):e2678. doi:10.1097/MD.0000000000002678.

64. Rouan GW, Lee TH, Cook EF, et al. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study). The American journal of cardiology. 1989;64:1087-92.

65. McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department: a review of the literature. J Gen Intern Med. 1990;5:365-73.

66. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281:707-13.

67. Diercks DB, Peacock WF, Hiestand BC, et al. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE initiative). Am J Cardiol. 2006;97:437-42.

68. Zalenski RJ, Rydman RJ, Sloan EP, et al. Value of posterior and right ventricular leads in comparison to the standard 12-lead electrocardiogram in evaluation of ST-segment elevation in suspected acute myocardial infarction. Am J Cardiol. 1997;79:1579-85.

69. Matetzky S, Freimark D, Feinberg MS, et al. Acute myocardial infarction with isolated ST-segment elevation in posterior chest leads V7-9: "hidden" ST-segment elevations revealing acute posterior infarction. J Am Coll Cardiol. 1999;34:748-53.

70. Fesmire FM, Percy RF, Bardoner JB, et al. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med. 1998;31:3-11.

71. Drozdov DV, Makarov LM, Barkan VS, et al. Resting 12-lead electrocardiography for adults and children. 2023 Guidelines. Russian Journal of Cardiology. 2023;28(10):5631. (In Russ.) Дроздов Д. В., Макаров Л. М., Баркан В. С. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/1560-4071-2023-5631. EDN: JAVUJL.

72. Drew BJ, Califf RM, Funk M, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the councils on cardiovascular nursing, clinical cardiology, and cardiovascular disease in the young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation. 2004;110: 2721-46.

73. Kalarus Z, Svendsen JH, Capodanno D, et al. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA) Europace. 2019;21:1603-4.

74. Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: Incidence, predictors, and outcomes. Circulation. 2002;106:309-12.

75. Auer J, Berent R. Early prediction of life-threatening arrhythmias in non-ST elevation myocardial infarction — does it change clinical practice? European Heart Journal: Acute Cardiovascular Care. 2015;4(1):37-40.

76. Zorzi A, Turri R, Zilio F, et al. At-admission risk stratification for in-hospital life-threatening ventricular arrhythmias and death in non-ST elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care. 2014;3(4):304-12. doi:10.1177/2048872614528796.

77. Katritsis DG, Siontis GC, Kastrati A, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J. 2011;32:32-40.

78. Elgendy IY, Mahmoud AN, Wen X, Bavry AA. Meta-Analysis of Randomized Trials of LongTerm All-Cause Mortality in Patients With Non-ST-Elevation Acute Coronary Syndrome Managed With Routine Invasive Versus Selective Invasive Strategies. Am J Cardiol. 2017;119:560-4.

79. Hong SJ, Kim BK, Shin DH, et al. Effect of intravascular ultrasound-guided vs angiographyguided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JAMA. 2015;314:2155-63. doi:10.1001/jama.2015.15454.

80. Zhang J, Gao X, Kan J, et al. Intravascular ultrasound versus angiography-guided drugeluting stent implantation: the ULTIMATE trial. J Am Coll Cardiol. 2018;72:3126-37. doi:10.1016/j.jacc.2018.09.013.

81. Gao XF, Ge Z, Kong XQ, et al. 3-Year outcomes of the ULTIMATE trial comparing intravascular ultrasound versus angiography-guided drug-eluting stent implantation. JACC Cardiovasc Interv. 2021;14:247-57. doi:10.1016/j.jcin.2020.10.001.

82. Meneveau N, Souteyrand G, Motreff P, et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: results of the multicenter, randomized DOCTORS study (Does Optical Coherence Tomography Optimize Results of Stenting). Circulation. 2016;134:906-17. doi:10.1161/circulationaha.116.024393.

83. Kala P, Cervinka P, Jakl M, et al. OCT guidance during stent implantation in primary PCI: a randomized multicenter study with nine months of optical coherence tomography followup. Int J Cardiol. 2018;250:98-103. doi:10.1016/j.ijcard.2017.10.059.

84. Johnson TW, Räber L, di Mario C, et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2019;40:2566-84. doi:10.1093/eurheartj/ehz332.

85. Sels JW, Tonino PA, Siebert U, et al. Fractional flow reserve in unstable angina and nonST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv. 2011;4:1183-9. doi:10.1016/j.jcin.2011.08.008.

86. Layland J, Oldroyd KG, Curzen N, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J. 2015;36:100-11. doi:10.1093/eurheartj/ehu338.

87. Ntalianis A, Sels JW, Davidavicius G, et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010;3:1274-81. doi:10.1016/j.jcin.2010.08.025.

88. Peper J, Becker LM, van Kuijk J-P, et al. Fractional Flow Reserve: Patient Selection and Perspectives. Vasc Health Risk Manag. 2021;17:817-31. doi:10.2147/VHRM.S286916.

89. Brueckmann M, Collinson P, Comaniciu D, et al. Early diagnosis of acute coronary syndrome. Eur Heart J. 2017;38:3049-55.

90. Lancellotti P, Price S, Edvardsen T, et al. The use of echocardiography in acute cardiovascular care: recommendations of the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care. 2015;4:3-5.

91. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-81.

92. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357: 1385-90.

93. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctioMareev Yu V. Dzhioeva ON, Zorya OT, et al. Focus ultrasound for cardiology practice. Russian consensus document. Kardiologiia. 2021;61(11):4-23. (In Russ.) Мареев Ю. В. Джиоева О. Н., Зоря О. Т. и др. Фокусное ультразвуковое исследование в кардиологической практике. Российский консенсусный документ. Кардиология. 2021; 61(11):4-23.

94. Goldschlager R, Roth H, Solomon J, et al. Validation of a clinical decision rule: chest X-ray in patients with chest pain and possible acute coronary syndrome. Emerg Radiol. 2014;21:367-72.

95. Claeys MJ, Ahrens I, Sinnaeve P, et al. The organization of chest pain units: Position statement of the Acute Cardiovascular Care Association. Eur Heart J: Acute Cardiovasc Care. 2017;6:203-11.

96. Kim HW, Faraneh-Far A, Kim RJ. Cardiovascular magnetic resonance in patients with myocardial infarction. J Am Coll Cardiol. 2009;55:1-16.

97. Beek AM, van Rossum AC. Cardiovascular magnetic resonance imaging in patients with acute myocardial infarction. Heart. 2010;96:237-43.

98. Fardman A, Massalha E, Natanzon SS, et al. Clinical predictors of left ventricular thrombus after myocardial infarction as detected by magnetic resonance imaging. Front Cardiovasc Med. 2024;10:1275390. doi:10.3389/fcvm.2023.

99. Velangi PS, Choo C, Chen KA, et al. Long-term embolic outcomes after detection of left ventricular thrombus by late gadolinium enhancement cardiovascular magnetic resonance imaging: a matched cohort study. Circ Cardiovasc Imaging. 2019;12:e009723. doi:10.1161/circimaging.119.009723.

100. Trippi JA, Lee KS. Dobutamine stress tele-echocardiography as a clinical service in the emergency department to evaluate patients with chest pain. Echocardiography. 1999;16:179-85.

101. Amsterdam EA, Kirk JD, Diercks DB, et al. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol. 2002;40:251-6.

102. Bholasingh R, Cornel JH, Kamp O, et al. Prognostic value of predischarge dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. J Am Coll Cardiol. 2003;41:596-602.

103. Gaibazzi N, Reverberi C, Badano L. Usefulness of contrast stress-echocardiography or 3458 exercise-electrocardiography to predict long-term acute coronary syndromes in patients presenting with chest pain without electrocardiographic abnormalities or 12-hour troponin levation. Am J Cardiol. 2011;107:161-7.

104. Lim SH, Anantharaman V, Sundram F, et al. Stress myocardial perfusion imaging for the evaluation and triage of chest pain in the emergency department: a randomized controlled trial. J Nucl Cardiol. 2013;20:1002-12.

105. Shah BN, Balaji G, Alhajiri A, et al. Incremental diagnostic and prognostic value of contemporary stress echocardiography in a chest pain unit: mortality and morbidity outcomes from a real-world setting. Circ Cardiovasc maging. 2013;6:202-9.

106. Nabi F, Kassi M, Muhyieddeen K, et al. Optimizing Evaluation of Patients with Low-toIntermediate-Risk Acute Chest Pain: A Randomized Study Comparing Stress Myocardial Perfusion Tomography Incorporating Stress-Only Imaging Versus Cardiac CT. J Nucl Med. 2016;57:378-84.

107. Çitaku H, Miftari R, Stubljar D, Krasniqi X. Size of Acute Myocardial Infarction Correlates with Earlier Time of Initiation of Reperfusion Therapy with Cardiac Perfusion Scintigraphy: A National Single-Center Study. Med Sci Monit Basic Res. 2021;27: e933214.

108. James O, Borges-Neto S. Scintigraphic outlook of patients and regions with myocardial necrosis at myocardial perfusion scintigraphy. J Nucl Cardiol. 2018;25(2):506-7. doi:10.1007/s12350-017-0796-0. Erratum in: J Nucl Cardiol. 2018;25(2):508. doi:10.1007/s12350-017-0861-8.

109. Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009;53: 1642-50.

110. Goldstein JA, Chinnaiyan KM, Abidov A, et al. Investigators C-S. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. J Am Coll Cardiol. 2011;58:1414-22.

111. Samad Z, Hakeem A, Mahmood SS, et al. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. J Nucl Cardiol. 2012;19:364-76.

112. Hoffmann U, Truong QA, Schoenfeld DA, et al., Investigators R-I. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med. 2012;367:299-308.

113. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med. 2012;366:1393-403.

114. Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013;61:880-92.

115. Dedic A, Lubbers MM, Schaap J, et al. Coronary CT Angiography for Suspected ACS in the Era of High-Sensitivity Troponins: Randomized Multicenter Study. J Am Coll Cardiol. 2016;67:16-26.

116. Goldstein JA, Gallagher MJ, O'Neill WW, et al. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol. 2007;49:863-71.

117. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Archives of internal medicine. 2003;163:2345-53.

118. Estes NA 3rd, Salem DN. Predictive value of the electrocardiogram in acute coronary syndromes. JAMA. 1999;281(8):753-4. doi:10.1001/jama.281.8.753.

119. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284:835-42.

120. D'Ascenzo F, Biondi-Zoccai G, Moretti C, et al. TIMI, GRACE and alternative risk scores in Acute Coronary Syndromes: a meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. Contemporary clinical trials. 2012;33:507-14.

121. Lippi G, Cervellin G. Assay characteristics and diagnostic improvement from contemporary to high-sensitivity troponin I immunoassays. Am J Med. 2013;126(9):e9-e10. doi:10.1016/j.amjmed.2013.02.040.

122. Haaf P, Reichlin T, Twerenbold R, et al. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. Eur Heart J. 2014;35:365-75.

123. Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA. 2000;284(7):876-8. doi:10.1001/ jama.284.7.876.

124. Stracke S, Dörr O, Heidt MC, et al. GRACE risk score as predictor of in-hospital mortality in patients with chest pain. Clin Res Cardiol. 2010;99(10):627-31. doi:10.1007/s00392010-0160-8.

125. Yan AT, Yan RT, Tan M, et al.; Canadian ACS Registry Investigators. ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. Am Heart J. 2006;152(2):270-6. doi:10.1016/j.ahj.2005.12.003.

126. Eagle KA, Lim MJ, Dabbous OH, et al.; Investigators G. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727-33.

127. Meune C, Drexler B, Haaf P, et al. The GRACE score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart. 2011;97:1479-83.

128. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333:1091.

129. Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4:e004425.

130. Simms AD, Reynolds S, Pieper K, et al. Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003-2009: National Institute for Cardiovascular Outcomes Research (NICOR). Heart. 2013;99:35-40.

131. Abu-Assi E, Raposeiras-Roubin S, Lear P, et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2012;1:222-31.

132. Costa F, van Klaveren D, James S, et al.; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389: 1025-34.

133. Wenzl FA, Kraler S, Ambler G, et al. Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation. Lancet. 2022;400:744-56. doi:10.1016/S0140-6736(22)01483-0.

134. Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40:2632-53. doi:10.1093/eurheartj/ehz372.

135. Минушкина Л. О., Эрлих А. Д., Бражник В. А., Затейщиков Д. А. Внешняя валидация шкалы риска кровотечений ОРАКУЛ с помощью базы данных регистра РЕКОРД 3. Кардиология. 2019;(12):5-10. doi:10.18087/cardio.2019.12.n677.

136. Бражник В. А., Минушкина Л. О., Аверкова А. О. и др. Шкалы риска кровотечений у больных с острым коронарным синдромом: место шкалы ОРАКУЛ. Кардиоваскулярная терапия и профилактика. 2020;19(5):2333. doi:10.15829/1728-8800-2020-2333.

137. Бражник В. А., Минушкина Л. О., Эрлих А. Д. и др. Использование шкалы ОРАКУЛ для оценки геморрагического риска у пациентов с острым коронарным синдромом и фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2021;17(1):11-5. doi:10.20996/1819-6446-2021-01-01.

138. Kolte D, Khera S, Dabhadkar KC, et al. Trends in coronary angiography, revascularization, and outcomes of cardiogenic shock complicating non-ST-elevation myocardial infarction. Am J Cardiol. 2016;117:1-9.

139. Mehta SR, Granger CB, Boden WE, et al.; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165-75.

140. Biondi-Zoccai G, Abbate A, Sangiorgi G. It's never too early! Evidence for rushing your acute coronary patients to the cath lab. Eur Heart J. 2011;32(1):13-5. doi:10.1093/eurheartj/ehq346.

141. Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and metaanalysis. Ann Intern Med. 2013;158:261-70.

142. Milasinovic D, Milosevic A, Marinkovic J, et al. Timing of invasive strategy in NSTE-ACS patients and effect on clinical outcomes: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis. 2015;241:48-54.

143. Bonello L, Laine M, Puymirat E, et al. Timing of Coronary Invasive Strategy in Non-STSegment Elevation Acute Coronary Syndromes and Clinical Outcomes: An Updated MetaAnalysis. JACC Cardiovasc Interv. 2016;9:2267-76.

144. Jobs A, Mehta SR, Montalescot G, et al. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: A meta-analysis of randomised trials. Lancet. 2017;390:737-46.

145. Kofoed KF, Kelbaek H, Hansen PR, et al. Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation. 2018;138:2741-50.

146. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48:1319-25.

147. Fox KA, Clayton TC, Damman P, et al., FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010; 55:2435-45.

148. Neumann FJ, Sousa-Uva M, Ahlsson A, et al.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165.

149. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial. Eur Heart J. 2019;40:283-91. doi:10.1093/eurheartj/ehy651.

150. Butt JH, Kofoed KF, Kelbæk H, et al. Importance of risk assessment in timing of invasive coronary evaluation and treatment of patients with non-ST-segment-elevation acute coronary syndrome: insights from the VERDICT trial. J Am Heart Assoc. 2021;10:e022333. doi:10.1161/jaha.121.022333.

151. Barbarawi M, Kheiri B, Zayed Y, et al. Meta-analysis of optimal timing of coronary intervention in non-ST-elevation acute coronary syndrome. Catheter Cardiovasc Interv. 2020;95:185-93. doi:10.1002/ccd.28280.

152. Fanning JP, Nyong J, Scott IA, et al. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database Syst Rev. 2016;2016(5):CD004815. doi:10.1002/14651858.CD004815.

153. Kite TA, Kurmani SA, Bountziouka V, et al. Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J. 2022;43(33):3148-61. doi:10.1093/eurheartj/ehac213.

154. O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008;300:71-80. doi:10.1001/jama.300.1.71.

155. Mehta SR, Cannon CP, Fox KAA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293:2908-17. doi:10.1001/jama.293.23.2908.

156. Sanchis J, Bodí V, Núñez J, Núñez E. Conservative, true selective invasive, and routine invasive strategies in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2010;56(19):1609; author reply 1609-10. doi:10.1016/j.jacc.2010.06.032.

157. Díez-Villanueva P, Jiménez-Méndez C, Cepas-Guillén P, et al. Current Management of Non-ST-Segment Elevation Acute Coronary Syndrome. Biomedicines. 2024;12(8):1736. doi:10.3390/biomedicines12081736.

158. Collet JP, Thiele H, Barbato E, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. doi:10.1093/ eurheartj/ehaa575. Erratum in: Eur Heart J. 2021;42(19):1908. Erratum in: Eur Heart J. 2021;42(19):1925.

159. Morici N, De Servi S, Toso A, et al. Renal dysfunction, coronary revascularization and mortality among elderly patients with non ST elevation acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2015;4(5):453-60. doi:10.1177/2048872614557221.

160. Nyman I, Wallentin L, Areskog M, et al. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC study group. Int J Cardiol. 1993;39:131-42.

161. Siontis GC, Mavridis D, Greenwood JP, et al. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ. 2018;360:k504.

162. Sardella G, Lucisano L, Garbo R, et al. Single-staged compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J Am Coll Cardiol. 2016;67:264-72. doi:10.1016/j.jacc.2015.10.082.

163. Siebert VR, Borgaonkar S, Jia X, et al. Meta-analysis comparing multivessel versus culprit coronary arterial revascularization for patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2019;124:1501-11. doi:10.1016/j.amjcard.2019.07.071.

164. Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385:2465-76.

165. Nardin M, Verdoia M, Barbieri L, et al. Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta-Analysis of Randomized Trials. Curr Vasc Pharmacol. 2017;16:79-92.

166. Nordmann AJ, Hengstler P, Leimenstoll BM, et al. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: A meta-analysis of randomized controlled trials. Eur Heart J. 2004;25:69-80.

167. Moses JW, Mehran R, Nikolsky E, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1165-71.

168. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-206.

169. Greenhalgh J, Hockenhull J, Rao N, et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev. 2010;5:CD004587.

170. Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012;308:777-87.

171. Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.

172. Valgimigli M, Patialiakas A, Thury A, et al.; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805-15.

173. Garot P, Morice MC, Tresukosol D, et al.; LEADERS FREE Investigators. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. J Am Coll Cardiol. 2017;69:162-71.

174. Darmoch F, Alraies MC, Al-Khadra Y, et al. Intravascular ultrasound imaging-guided versus coronary angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e013678. doi:10.1161/jaha.119.013678.

175. Jia H, Dai J, He L, et al. EROSION III: a multicenter RCT of OCT-guided reperfusion in STEMI with early infarct artery patency. JACC Cardiovasc Interv. 2022;15:846-56. doi:10.1016/j.jcin.2022.01.298.

176. Kim Y, Bae S, Johnson TW, et al.; KAMIR‐NIH (Korea Acute Myocardial Infarction Registry‐National Institutes of Health) Investigators [Link]. Role of Intravascular UltrasoundGuided Percutaneous Coronary Intervention in Optimizing Outcomes in Acute Myocardial Infarction. J Am Heart Assoc. 2022;11(5):e023481. doi:10.1161/JAHA.121.023481.

177. Kobayashi Y, Lønborg J, Jong A, et al. Prognostic value of the residual SYNTAX score after functionally complete revascularization in ACS. J Am Coll Cardiol. 2018;72:1321-9. doi:10.1016/j.jacc.2018.06.069.

178. Lee JM, Kim HK, Park KH, et al. Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivesse disease: a randomized trial. Eur Heart J. 2023;44:473-84. doi:10.1093/eurheartj/ehac763.

179. Подметин П. С., Бурак Т. Я., Кочанов И. Н., Каледин А. Л. Аугментация гиперемии введением дополнительного гиперемирующего агента при пограничных значениях фракционного резерва кровотока. Эндоваскулярная хирургия. 2019;6(1):13-9. doi:10.24183/24094080-2019-6-1-13-19.

180. De Bruyne B, Pijls NH, Barbato E, et al. Intracoronary and intravenous adenosine 5'-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation. 2003;107(14):1877-83. doi:10.1161/01.CIR.0000061950.24940.88.

181. Van der Voort PH, van Hagen E, Hendrix G, et al. Comparison of intravenous adenosine to intracoronary papaverine for calculation of pressure-derived fractional flow reserve. Cathet. Cardiovasc. Diagn. 1996;39(2):120-5. doi:10.1002/(SICI)1097-0304(199610)39:23.0.CO;2-H19.

182. Nishi T, Kitahara H, Iwata Y, et al. Efficacy of combined administration of intracoronary papaverine plus intravenous adenosine 5'-triphosphate in assessment of fractional flow reserve. J. Cardiol. 2016;68(6):512-6. doi:10.1016/j.jjcc.2015.12.005.

183. Li Kam Wa ME, De Silva K, Collet C, Perera D. FLOWER-MI and the root of the problem with non-culprit revascularisation. Open heart. 2021;8(2):e001763. doi:10.1136/openhrt-2021-001763.

184. Cuculi F, De Maria GL, Meier P, et al. Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;64:1894-904. doi:10.1016/j.jacc.2014.07.987.

185. De Bruyne B, Pijls NH, Bartunek J, et al. Fractional flow reserve in patients with prior myocardial infarction. Circulation. 2001;104:157-62. doi:10.1161/01.cir.104.2.157.

186. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120:851-8.

187. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-9.

188. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48:924-30.

189. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189-96.

190. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300:1038-46.

191. Maioli M, Toso A, Leoncini M, et al. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. Circ Cardiovasc Interv. 2011;4:456-62.

192. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrastinduced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, openlabel, non-inferiority trial. Lancet. 2017;389:1312-22.

193. Giacoppo D, Gargiulo G, Buccheri S, et al. Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28240 Patients. Circ Cardiovasc Interv. 2017;10. doi:10.1161/CIRCINTERVENTIONS.116.004383.

194. Tweet MS, Eleid MF, Best PJM, et al. Spontaneous coronary artery dissection: revascularization versus conservative therapy. Circ Cardiovasc Interv. 2014;7:777-86. doi:10.1161/circinterventions.114.001659.

195. Hayes SN, Tweet MS, Adlam D, et al. Spontaneous coronary artery dissection: JACC Stateof-the-Art Review. J Am Coll Cardiol. 2020;76:961-84. doi:10.1016/j.jacc.2020.05.084.

196. Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, Acute Cardiovascular Care Association, SCAD study group: a position paper on spontaneous coronary artery dissection. Eur Heart J. 2018;39:3353-68. doi:10.1093/eurheartj/ehy080.

197. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999; 341:625-34. doi:10.1056/NEJM199908263410901.

198. Thiele H, Akin I, Sandri M, et al., Investigators C-S. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med. 2018;379:1699-710.

199. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST segment elevation: one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol. 2020;5:1358-65. doi:10.1001/jamacardio.2020.3670.

200. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41: 3504-20. doi:10.1093/eurheartj/ehaa503.

201. Pathik B, Raman B, Mohd Amin NH, et al. Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1146-52. doi:10.1093/ehjci/jev289.

202. Reynolds HR, Maehara A, Kwong RY, et al. Coronary optical coherence tomography and cardiac magnetic resonance imaging to determine underlying causes of myocardial infarction with nonobstructive coronary arteries in women. Circulation. 2021;143:624-40. doi:10.1161/circulationaha.120.052008.

203. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149:1043-9.

204. Iakobishvili Z, Cohen E, Garty M, et al. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care. 2011;13:76-80.

205. Duarte GS, Nunes-Ferreira A, Rodrigues FB, et al. Morphine in acute coronary syndrome: systematic review and meta-analysis. BMJ Open. 2019;9:e025232.

206. Ghadban R, Enezate T, Payne J, et al. The safety of morphine use in acute coronary syndrome: a meta-analysis. Heart Asia. 2019;11:e011142.

207. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015; 8:e001593. doi:10.1161/circinterventions.114.001593.

208. Saad M, Meyer-Saraei R, de Waha-Thiele S, et al. Impact of morphine treatment with and without metoclopramide coadministration on ticagrelor-induced platelet inhibition in acute myocardial infarction: the randomized MonAMI trial. Circulation. 2020;141:1354-6. doi:10.1161/circulationaha.119.042816.

209. Murphy B, Le Grande M, Alvarenga M, et al. Anxiety and depression after a cardiac event: prevalence and predictors. Front Psychol. 2019;10:3010. doi:10.3389/fpsyg. 2019.03010.

210. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011;2011(9):CD008012. doi:10.1002/14651858.CD008012.pub3.

211. Moser DK. "The rust of life": impact of anxiety on cardiac patients. Am J Crit Care. 2007;16:361-9. doi:10.4037/ajcc2007.16.4.361.

212. Farquhar H, Weatherall M, Wijesinghe M, et al. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Heart J. 2009;158:371-7.

213. Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in cardiac patients. JACC. 2010;56:1013-6.

214. Stub D, Smith K, Bernard S, et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation. 2015;131:2143-50. doi:10.1161/circulationaha.114.014494.

215. Cabello JB, Burls A, Emparanza JI, et al. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. 2016;12:CD007160.

216. Hofmann R, James SK, Jernberg T, et al.; for the DETO2X–SWEDEHEART Investigators. Oxygen Therapy in Suspected Acute Myocardial Infarction. E Engl J Med. 2017;377:12409. doi:10.1056/NEJMoa1706222.

217. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med. 1983;309:396-403.

218. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369-75.

219. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-11.

220. The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-30.

221. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.

222. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.

223. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-39.

224. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345: 494-502.

225. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.

226. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.

227. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33.

228. Mehta SR, Tanguay JF, Eikelboom JW, et al.; for CURRENT-OASIS Trial Investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233-43.

229. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.

230. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecularweight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet. 2000;355:1936-42.

231. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-76.

232. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339-49.

233. Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553.

234. Cohen M, Mahaffey KW, Pieper K, et al.; on behalf of the SYNERGY Trial Investigators. A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial Enoxaparin Versus Unfractionated Heparin in Non-STSegment Elevation Acute Coronary Syndromes. JACC. 2006;48:1346-54.

235. Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial. Circulation. 2005;111:1390-7.

236. Cassese S, Byrne RA, Laugwitz KL, et al. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention. 2015;11:196-203.

237. Zhang S, Gao W, Li H, et al. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Int J Cardiol. 2016;209:87-95.

238. Erlinge D, Omerovic E, Frobert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017;377:1132-42.

239. Nuhrenberg TG, Hochholzer W, Mashayekhi K, et al. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. Clin Res Cardiol. 2018;107:807-15.

240. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981-9.

241. Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65:1619-29.

242. Dewilde WJ, Janssen PW, Kelder JC, et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention. 2015;11:381-90.

243. Dewilde WJ, Oirbans T, Verheugt FW, et al.; WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet. 2013;381:1107-15.

244. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423-34.

245. Cannon CP, Bhatt DL, Oldgren J, et al.; RE-DUAL Steering Committee PCI and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-24.

246. Lopes RD, Heizer G, Aronson R, et al.; for the AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation NEJM. 2019; 380:1509-24.

247. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40;3757-67.

248. Lopes RD, Hong H, Harskamp RE, et al. Optimal Antithrombotic Regimes for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. An Updated Network Meta-analysis. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2019.6175.

249. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012; 126:1185-93.

250. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634-40.

251. Kopin D, Jones WS, Sherwood MW, et al. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J. 2018;197:133-41.

252. Kuno T, Watanabe A, Shoji S, et al. Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. Circ Cardiovasc Interv. 2023;16(9):e013242. doi:10.1161/CIRCINTERVENTIONS.123.013242.

253. Wang W, Huang Q, Pan D, et al. The optimal duration of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. Int J Cardiol. 2022;357:33-8. doi:10.1016/j.ijcard.2022.03.047.

254. Kuno T, Ueyama H, Takagi H, Bangalore S. The risk of stent thrombosis of dual antithrombotic therapy for patients who require oral anticoagulant undergoing percutaneous coronary intervention: insights of a meta-analysis of randomized trials. Scand Cardiovasc J. 2022;56(1):1-3. doi:10.1080/14017431.2021.2025264.

255. Gupta R, Malik AH, Gupta R, et al. Dual Versus Triple Therapy in Patients with Acute Coronary Syndrome and an Anticoagulation Indication: A Systematic Review with MetaAnalysis and Trial-Sequential Analysis. Cardiol Rev. 2021;29(5):245-52. doi:10.1097/CRD.0000000000000320.

256. Agarwal N, Mahmoud AN, Mojadidi MK, et al. Dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention-meta-analysis and metaregression. Cardiovasc Revasc Med. 2019;20(12):1134-9. doi:10.1016/j.carrev.2019.02.022.

257. Zhang J, Wang Z, Sang W, et al. Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis. Coron Artery Dis. 2019;30(2):109-15. doi:10.1097/MCA.0000000000000698.

258. Shah R, Khan SA, Khan B, Latham SB. Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a metaanalysis of randomized clinical trials. Coron Artery Dis. 2019;30(2):116-23. doi:10.1097/MCA.0000000000000690.

259. Shin D, Mohanty BD, Lee ES. Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis. Coron Artery Dis. 2018;29(8):670-80. doi:10.1097/MCA.0000000000000660.

260. Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2018;39:213-60.

261. Schü e S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524-34. doi:10.1056/NEJMoa1908973.

262. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-STsegment elevation acute coronary syndromes. N Engl J Med. 2013;369:999-1010. doi:10.1056/NEJMoa1308075.

263. Tarantini G, Mojoli M, Varbella F, et al. Timing of oral P2Y(12) inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome. JACC. 2020;76:2450-9. doi:10.1016/j.jacc.2020.08.053.

264. Dworeck C, Redfors B, Angerås O, et al. Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. JAMA Netw Open. 2020;3:e2018735. doi:10.1001/jamanetworkopen.2020.18735.

265. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20. doi:10.1001/jama.288.19.2411.

266. Dawson LP, Chen D, Dagan M, et al. Assessment of pretreatment with oral P2Y12 inhibitors and cardiovascular and bleeding outcomes in patients with non-ST elevation acute coronary syndromes: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2134322. doi:10.1001/jamanetworkopen.2021.34322.

267. Fox KA, Mehta SR, Peters R, et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome. The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202-8.

268. Wiviott SD, White HD, Ohman EM, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013;382:605-13. doi:10.1016/s0140-6736(13)61451-8.

269. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527. doi:10.1136/bmj.d3527.

270. Kohli P, Wallentin L, Reyes E, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013;127(6): 673-80. doi:10.1161/CIRCULATIONAHA.112.1242487.

271. Kleiman NS. PLATO study of ticagrelor versus clopidogrel in patients with high-risk acute coronary syndromes. Curr Cardiol Rep. 2010;12(4):283-5. doi:10.1007/s11886010-0114-9.

272. Coughlan JJ, Aytekin A, Lahu S, et al. Ticagrelor or prasugrel for patients with acute coronary syndrome treated with percutaneous coronary intervention: a prespecified subgroup analysis of a randomized clinical trial. JAMA Cardiol. 2021;6:1121-9. doi:10.1001 jamacardio.2021.2228.

273. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, openlabel, non-inferiority trial. Lancet. 2020;395: 1374-81. doi:10.1016/s0140-6736(20)30325-1.

274. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012;5:680-8. doi:10.1161/circoutcomes.111.964395.

275. Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation. 2020;142:1700-8. doi:10.1161/circulationaha.120.050645.

276. Khan SU, Khan MZ, Asad ZUA, et al. Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(4):913-20. doi:10.1007/s11239-020-02114-7.

277. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA. 2007;297:591-602.

278. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360:2176-90.

279. Sehested TSG, Carlson N, Hansen PW, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019;40:1963-70.

280. Bhatt DL, Cryer BL, Contant CF, et al.; for the COGENT Investigators. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med. 2010;363:1909-17.

281. Kwok CSh, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: Metaanalysis. Int J Cardiol. 2012;167:965-74.

282. Huang B, Huang Y, Li Y, et al. Adverse Cardiovascular Effects of Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis. Archives of Medical Research. 2012;43:212-24.

283. Melloni C, Washam JB, Jones WS, et al. Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy. Systematic Review. Circ Cardiovasc Qual Outcomes. 2015;8:47-55.

284. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-97. doi:10.1016/s0140-6736(09)61525-7.

285. Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125:978-86. doi:10.1161/circulationaha.111.032912.

286. Long M, Ye Z, Zheng J, et al. Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a metaanalysis. BMC Pharmacol Toxicol. 2020;21:31. doi:10.1186/s40360-020-00409-2.

287. Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients. Eur Heart J. 2017;38:1034-43. doi:10.1093/eurheartj/ehw627.

288. Hahn J-Y, Song YB, Oh J-H, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321:2428-37. doi:10.1001/jama.2019.8146.

289. Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomized superiority trial. Lancet. 2018;392:940-9. doi:10.1016/s0140-6736(18)31858-0.

290. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032-42. doi:10.1056/NEJMoa1908419.

291. Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323:2407-16. doi:10.1001/jama.2020.7580.

292. Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with secondgeneration drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2021;42:308-19. doi:10.1093/eurheartj/ehaa739.

293. Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021;373:n1332. doi:10.1136/bmj.n1332.

294. Smits PC, Frigoli E, Tijssen J, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapyafter coronary stenting: an open-label, randomized, controlled trial. Circulation. 2021;144:1196-211. doi:10.1161/circulationaha.121.056680.

295. Watanabe H, Morimoto T, Natsuaki M, et al.; STOPDAPT-2 ACS Investigators. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022;7(4):407-17. doi:10.1001/jamacardio.2021.5244.

296. Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, openlabel, multicentre trial. Lancet. 2017;390:1747-57. doi:10.1016/s0140-6736(17)32155-4.

297. Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070-8. doi:10.1093/eurheartj/ehx175.

298. Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398:1305-16. doi:10.1016/s01406736(21)01445-8.

299. Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621-31. doi:10.1056/NEJMoa1907096.

300. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811-5. doi:10.1001/jama.1996.03540100055028.

301. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in highrisk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54. doi:10.1001/jama.292.1.45.

302. James S. Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention. BMJ. 2012;344:e712. doi:10.1136/bmj.e712.

303. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE metaanalysis. Circulation. 1999;100:1602-8. doi:10.1161/01.cir.100.15.1602.

304. Martin JL, Fry ETA, Sanderink G.-JCM, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Cardiovasc Interv. 2004;61:163-70. doi:10.1002/ccd.10726.

305. Cohen M, Levine GN, Pieper KS, et al.; SYNERGY Trial Investigators. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv. 2010;75:928-35. doi:10.1002/ccd.22340.

306. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383:955-62.

307. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonistbased antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394:1335-43. doi:10.1016/s0140-6736(19)31872-0.

308. Carter NJ, Plosker GL. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs. 2013;73(7):715-39. doi:10.1007/s40265-013-0056-9.

309. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2020;42:373-498.

310. Ray WA, Chung CP, Murray KT, et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA. 2018;320:2221-30. doi:10.1001/jama.2018.17242.

311. Moayyedi P, Eikelboom JW, Bosch J, et al.; COMPASS Investigators. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Gastroenterology. 2019;157(2): 403-12. doi:10.1053/j.gastro.2019.04.041.

312. Lee SR, Kwon S, Choi EK, et al. Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. Cardiovasc Drugs Ther. 2022;36:679-89. doi:10.1007/s10557-02107170-6.

313. Ahn HJ, Lee SR, Choi EK, et al. Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:4676-87. doi:10.1111/bcp.15478.

314. Hahn J-Y, Song YBin, Oh J-H, et al.; for the SMART-DATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391:1274-84.

315. Mauri L, Kereiakes DJ, Yeh RW, et al.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66.

316. Costa F, Adamo M, Ariotti S, et al. Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. Int J Cardiol. 2015;201:179-81.

317. Hermiller JB, Krucoff MW, Kereiakes DJ, et al.; DAPT Study Investigators. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC Cardiovasc Interv. 2016;9:138-47.

318. Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37: 390-9.

319. Bonaca MP, Bhatt DL, Cohen M, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800.

320. Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133-42.

321. Eikelboom JW, Connolly SJ, Bosch JD, et al.; for the COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-30. doi:10.1056/NEJMoa1709118.

322. Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395:1487-95. doi:10.1016/s01406736(20)30315-9.

323. Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigatorinitiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397:248796. doi:10.1016/s0140-6736(21)01063-1.

324. Leonardi S, Franzone A, Piccolo R, et al. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open. 2019;9(3):e026053. doi:10.1136/bmjopen-2018-026053.

325. Franzone A, McFadden E, Leonardi S, et al.; GLASSY Investigators. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. J Am Coll Cardiol. 2019;74(18):2223-34. doi:10.1016/j.jacc.2019.08.1038.

326. Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin inhibition in myocardial ischemia. Am J Cardiol. 1998;81:678-81.

327. Melandri G, Branzi A, Tartagni F, et al. Haemodynamic effects of metoprolol and intravenous nitroglycerin versus metoprolol alone in patients with acute myocardial infarction. Eur Heart J. 1987;8:592-6.

328. Zharov EI, Vertkin AL, Martynov AI, Salnikov SN. Comparative evaluation of intravenous isosorbide dinitrate and nitroglycerin in patients with acute myocardial infarction. Cardiology. 1991;79 Suppl 2:63-9. doi:10.1159/000174927.

329. Hirota Y, Saito T, Kita Y, et al. Intravenous isosorbide dinitrate infusion in the management of unstable angina pectoris refractory to conventional medical therapy. Jpn Circ J. 1987;51(6):617-23. doi:10.1253/jcj.51.617.

330. Kojima S, Matsui K, Sakamoto T, et al.; on behalf of the Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. Circ J. 2007;71:301-7.

331. Miyazaki S, Nonogi H, Goto Y, et al. Comparison of the therapeutic efficacy of continuous and intermittent injection of isosorbide dinitrate: a randomized study on unstable angina. Intern Med. 1995;34(9):856-62. doi:10.2169/internalmedicine.34.856.

332. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7.

333. Ellis K, Tcheng JE, Sapp S, et al. Mortality benefit of beta-blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from Epic, Epilog, Capture and Rapport trials. J Interven Cardiol. 2003;16:299-305.

334. Miller CD, Roe MT, Mulgund J, et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med. 2007;120:685-92.

335. Chatterjee S, Chaudhuri D, Vedanthan R, et al. Early intravenxous beta-blockers in patients with acute coronary syndrome — a meta-analysis of randomized trials. Int J Cardiol. 2013;168:915-21.

336. Andersson C, Shilane D, Go AS, et al. Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64:247-52.

337. Bangalore S, Makani H, Radford M, et al. Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials. Am J Med. 2014;127:939-53.

338. Puymirat E, Riant E, Aissoui Na, et al. β-blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016; 354:i4801.

339. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal. 2022;43:3997-4126.

340. CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.

341. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-7.

342. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8.

343. Maclean E, Zheng S, Nabeebaccus A, et al. Effect of early bisoprolol administration on ventricular arrhythmia and cardiac death in patients with non-ST elevation myocardial infarction. Heart Asia. 2015;7(2):46-51. doi:10.1136/heartasia-2015-010675.

344. de Peuter OR, Lussana F, Peters RJ, et al. A systematic review of selective and nonselective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67:284-94.

345. Munkhaugen J, Ruddox V, Halvorsen S, et al. BEtablocker treatment after acute myocardial infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J. 2019;208:37-46.

346. Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020;21:1-11.

347. Rossello X, Raposeiras-Roubin S, Latini R, et al. Rationale and design of the pragmatic clinical trial tREatment with beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother. 2022;8(3):291-301.

348. Yndigegn T, Lindahl B, Alfredsson J, et al. Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI). Eur Heart J Cardiovasc Pharmacother. 2023;9(2):192-7. doi:10.1093/ehjcvp/pvac070.

349. Safi S, Sethi NJ, Korang SK, et al. Beta-blockers in patients without heart failure after myocardial infarction. Cochrane Database Syst Rev. 2021;11(11):CD012565. doi:10.1002/14651858.

350. Wen XS, Luo R, Liu J, et al. Short-term/long-term prognosis with or without betablockers in patients without heart failure and with preserved ejection fraction after acute myocardial infarction: a multicenter retrospective cohort study. BMC Cardiovasc Disord. 2022;22(1):193. doi:10.1186/s12872-022-02631-8.

351. Won H, Suh Y, Kim GS, et al. Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database. Korean Circ J. 2020; 50(6):499-508. doi:10.4070/kcj.2019.0231.

352. Sakagami A, Soeda T, Saito Y, et al.; J-MINUET investigators. Clinical impact of betablockers at discharge on long-term clinical outcomes in patients with non-reduced ejection fraction after acute myocardial infarction. J Cardiol. 2023;81(1):83-90. doi:10.1016/j.jjcc.2022.08.002.

353. Desta L, Khedri M, Jernberg T, et al. Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction. ESC Heart Fail. 2021;8(1): 344-55. doi:10.1002/ehf2.13079.

354. Song PS, Kim M, Seong SW, et al. Heart failure with mid-range ejection fraction and the effect of β-blockers after acute myocardial infarction. Heart Vessels. 2021;36(12):184855. doi:10.1007/s00380-021-01876-1.

355. Velásquez-Rodríguez J, Bruña V, Vicent L, et al. Influence of left ventricular systolic function on the long-term benefit of beta-blockers after ST-segment elevation myocardial infarction. Rev Port Cardiol (Engl Ed). 2021;40(4):285-90. doi:10.1016/j.repc.2020.07.017.

356. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Qwave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986;315:423-9.

357. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J. 1986;56:400-13.

358. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. 1987;60:18A-25A.

359. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299:1187-92.

360. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol. 1990;66:779-85.

361. Moss AJ, Oakes D, Rubison M, et al. Effects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol. 1991;68:429-33.

362. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol. 1996;77:365-9.

363. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol. 1998;21:633-41.

364. Smith NL, Reiber GE, Psaty BM, et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol. 1998;32:1305-11.

365. Beltrame JF, Crea F, Kaski JC, et al.; Coronary Vasomotion Disorders International Study Group (COVADIS). The Who, What, Why, When, How and Where of Vasospastic Angina. Circ J. 2016;80:289-98.

366. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.

367. Fox KM; European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-8.

368. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. doi:10.1056/NEJMoa0801317.

369. Bangalore S, Fakheri R, Wandel S, et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and metaanalysis of randomized trials. BMJ. 2017;356:j4.

370. Pfeffer MA, Braunwald E, Moye LA, et al. SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.

371. Ball SG, Hall AS, Murray GD. ACE inhibition, atherosclerosis and myocardial infarction — the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study. Eur Heart J. 1994;15(Suppl B):20-5.

372. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-85.

373. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997;95:2643-51.

374. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998;97:2202-12.

375. Pop D, Dădârlat-Pop A, Tomoaia R, et al. Updates on the Renin-Angiotensin-Aldosterone System and the Cardiovascular Continuum. Biomedicines. 2024;12(7):1582. doi:10.3390/biomedicines12071582.

376. Borghi C, Omboni S, Reggiardo G, et al.; on behalf of the SMILE Working Project. Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies. J Cardiovasc Pharmacol. 2017;69:48-54.

377. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.

378. Weber MA. Telmisartan in high-risk cardiovascular patients. Am J Cardiol. 2010;105 (1 Suppl):36A-43A. doi:10.1016/j.amjcard.2009.10.008.

379. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan 5688 in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to 5689 angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lance. 2003;362772-6.

380. Berwanger O, Pfeffer M, Claggett D, et al. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. European Journal of Heart Failure. 2022. doi:10.1002/ejhf.2663.

381. Gu J, Wang Y, Wang CQ, Zhang JF. The initial timing and dosage pattern of sacubitril/ valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Eur J Intern Med. 2023:S0953-6205(23)00091-2. doi:10.1016/j.ejim.2023.03.019.

382. Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23(6):1040-8. doi:10.1002/ejhf.2191.

383. Lin G, Chen W, Wu M, et al. The value of sacubitril/valsartan in acute anterior wall ST-segment elevation myocardial infarction before emergency Percutaneous coronary intervention. Cardiology. 2022. doi:10.1159/000527357.

384. Mehran R, Steg PhG, Pfeffer MA, et al. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation. 2022;146:1749-57. doi:10.1161/ CIRCULATIONAHA.122.060841.

385. Pfeffer MA, Claggett B, Lewis EF, et al. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022;145:87-9. doi:10.1161/CIRCULATIONAHA.121.057429.

386. Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021;385:1845-55. doi:10.1056/ NEJMoa2104508.

387. Rezq A, Saad M, El Nozahi M. Comparison of the Efficacy and Safety of Sacubitril/ Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2021;143:7-13. doi:10.1016/j.amjcard.2020.12.037.

388. Shah AM, Claggett B, Prasad N, et al. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation. 2022;146:1067-81. doi:10.1161/ CIRCULATIONAHA.122.059210.

389. Xiong B, Nie D, Qian J, et al. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(6): 4852-62. doi:10.1002/ehf2.13677.

390. Yang P, Han Y, Lian C, Wu X. Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis. Front Cardiovasc Med. 2022;9:988117. doi:10.3389/fcvm.2022.988117.

391. Zhou X, Zhu H, Zheng Y, et al. A systematic review and meta-analysis of sacubitrilvalsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction. Front Cardiovasc Med. 2022;9:953948. doi:10.3389/fcvm. 2022.953948.

392. McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.

393. Prabhakar M, Massel D. Adjunctive treatment with eplerenone reduced morbidity and mortality in acute myocardial infarction. ACP J Club. 2003;139(2):32.

394. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.

395. Bossard M, Binbraik Y, Beygui F, et al. Mineralocorticoid Receptor Antagonists in Patients with Acute Myocardial Infarction — A Systematic Review and Meta-analysis of Randomized Trials. Am Heart J. 2018;195:60-9.

396. Schwartz GG, Olsson AG, Ezekowitz MD, et al.; for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. The MIRACL Study: A Randomized Controlled Trial. JAMA. 2001;285:1711-8.

397. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.

398. Hulten E, Jackson JL, Douglas K, et al. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. A Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 2006;166:1814-21.

399. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.

400. Cholesterol Treatment Trialists Collaboration, Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385: 1397-405.

401. Navarese EP, Kowalewski M, Andreotti F, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113:1753-64. doi:10.1016/j.amjcard.2014.02.034.

402. Nusca A, Melfi R, Patti G, Sciascio GD. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. Future Cardiol. 2010;6(5):579-89. doi:10.2217/fca.10.77.

403. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97.

404. Jukema JW, Szarek M, Zijlstra LE, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167-76. doi:10.1016/j.jacc.2019.03.013.

405. Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452-62. doi:10.1016/j.jacc.2019.08.010.

406. Trankle CR, Wohlford G, Buckley LF, et al. Alirocumab in acute myocardial infarction: results from the Virginia commonwealth university alirocumab response trial (VCU-AlirocRT). J Cardiovasc Pharmacol. 2019;74(3):266-9. doi:10.1097/FJC.0000000000000706.

407. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-81. doi:10.1001/jama. 2022.5218.

408. Ray KK, Wright RS, Khaled D, et al.; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-19. doi:10.1056/NEJMoa1912387.

409. Lee J, Egolum U, Parihar H, et al. Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. Cardiol Res. 2021;12(2):98-108. doi:10.14740/cr1224.

410. Wang X, Wen D, Chen Y, et al. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovasc Diabetol. 2022;21(1):107. doi:10.1186/s12933-022-01542-4.

411. Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830-3. doi:10.1093/eurheartj/ehab718.

412. Burnett H, Fahrbach K, Cichewicz A, et al. Comparative efficacy of non-statin lipidlowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022;38(5):777-84. doi:10.1080/03007995.2022.2049164.

413. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020;134:69-73. doi:10.1016/j.amjcard.2020.08.018.

414. Ray KK, Raal FJ, Kallend DG, et al.; ORION Phase III investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129-38. doi:10.1093/eurheartj/ehac594.

415. Sabatine MS, Giugliano RP, Keech AC, et al.; for the FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomesin Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713-22.

416. Schwartz GG, Steg PG, Szarek M, et al.; for the ODYSSEY OUTCOMES Committees and Investigators. Аlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097-107.

417. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER. Circulation. 2018;138:756-66.

418. NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-97. doi:10.1056/NEJMoa0810625.

419. Kovalaske MA, Gandhi GY. ACP Journal Club. Intensive glucose control increased risk for death and severe hypoglycemia in critically ill adults. Ann Intern Med. 2009;151(4):JC2-5. doi:10.7326/0003-4819-151-4-200908180-02005.

420. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995; 26:57-65.

421. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512-5.

422. Mamas MA, Neyses L, Fath-Ordoubadi F. A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol. 2010; 15:e20-e24.

423. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113: 2906-13.

424. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302-8.

425. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549-56. doi:10.1056/NEJMoa012689.

426. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557-63. doi:10.1056/NEJMoa003289.

427. Belliard G, Catez E, Charron C, et al. Efficacy of therapeutic hypothermia after outof-hospital cardiac arrest due to ventricular fibrillation. Resuscitation. 2007;75:252-9. doi:10.1016/j.resuscitation.2007.04.014.

428. Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33 °C versus 36 °C after cardiac arrest. N Engl J Med. 2013;369:2197-206. doi:10.1056/NEJMoa1310519.

429. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2021;384(24):2283-94. doi:10.1056/NEJMoa2100591.

430. Wolfrum S, Roedl K, Hanebutte A, et al. Temperature control after in-hospital cardiac arrest: a randomized clinical trial. Circulation. 2022;146:1357-66. doi:10.1161/circulationaha.122.060106.

431. Vaahersalo J, Hiltunen P, Tiainen M, et al. Therapeutic hypothermia after out-of-hospital cardiac arrest in Finnish intensive care units: the FINNRESUSCI study. Intensive Care Med. 2013;39:826-37. doi:10.1007/s00134-013-2868-1.

432. Okazaki T, Hifumi T, Kawakita K, Kuroda Y; Japanese Association for Acute Medicine outof-hospital cardiac arrest (JAAM-OHCA) registry. Targeted temperature management guided by the severity of hyperlactatemia for out-of-hospital cardiac arrest patients: a post hoc analysis of a nationwide, multicenter prospective registry. Ann Intensive Care. 2019;9(1):127. doi:10.1186/s13613-019-0603-y.

433. Callaway CW, Coppler PJ, Faro J, et al. Association of Initial Illness Severity and Outcomes After Cardiac Arrest With Targeted Temperature Management at 36 °C or 33 °C. JAMA Netw Open. 2020;3(7):e208215. doi:10.1001/jamanetworkopen.2020.8215.

434. Nishikimi M, Ogura T, Nishida K, et al. Outcome Related to Level of Targeted Temperature Management in Postcardiac Arrest Syndrome of Low, Moderate, and High Severities: A Nationwide Multicenter Prospective Registry. Crit Care Med. 2021;49(8):e741-e750. doi:10.1097/CCM.0000000000005025.

435. Lascarrou JB, Merdji H, Le Gouge A, et al. Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm. N Engl J Med. 2019;381(24):2327-37. doi:10.1056/NEJMoa190666.

436. Perkins GD, Graesner JT, Semeraro F, et al. European Resuscitation Council Guidelines 2021: executive summary. Resuscitation. 2021;161:1-60. doi:10.1016/j.resuscitation.2021.02.003.

437. Bonnefoy-Cudraz E, Bueno H, Casella G, et al. Editor's Choice – acute cardiovascular care association position paper on intensive cardiovascular care units: an update on their definition, structure, organisation and function. Eur Heart J Acute Cardiovasc Care. 2018;7:80-95. doi:10.1177/2048872617724269.

438. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. Am. J. Cardiol. 1967;20(4):457-64.

439. Khot UN, Jia G, Moliterno DJ, et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. JAMA. 2003;290(16):2174-81.

440. Masip J, Peacock WF, Price S, et al., Acute Heart Failure Study Group of the Acute Cardiovascular Care Association and the Committee on Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology. Indications and practical approach to non-invasive ventilation in acute heart failure. Eur Heart J. 2018;39:1725.

441. Weng CL, Zhao YT, Liu QH, et al. Meta-analysis: non-invasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010;152(9):590-600.

442. ФGray A, Goodacre S, Newby DE, et al. 3CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-51.

443. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021;42:3599-726.

444. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion–a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-55. doi:10.1002/ejhf.1369.

445. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-40.

446. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389-93.

447. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50:144-52.

448. Kozhuharov N, Goudev A, Flores D, et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA. 2019;322: 2292-302.

449. Freund Y, Cachanado M, Delannoy Q, et al. Effect of an emergency department care bundle on 30-day hospital discharge and survival among elderly patients with acute heart failure: the ELISABETH randomized clinical trial. JAMA. 2020;324:1948-56.

450. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25:205-9.

451. Gil V, Dominguez-Rodriguez A, Masip J, et al. Morphine use in the treatment of acute cardiogenic pulmonary edema and its effects on patient outcome: a systematic review. Curr Heart Fail Rep. 2019;16:81-8.

452. Miro O, Gil V, Martin-Sanchez FJ, et al.; ICA-SEMES Research Group. Morphine use in the ED and outcomes of patients with acute heart failure: a propensity score-matching analysis based on the EAHFE registry. Chest. 2017;152:821-32.

453. Caspi O, Naami R, Halfin E, Aronson D. Adverse dose-dependent effects of morphine therapy in acute heart failure. Int J Cardiol. 2019;293:131-6.

454. Hochman JS, Buller CE, Sleeper LA, et al.; for the SHOCK Investigators. Cardiogenic Shock Complicating Acute Myocardial Infarction — Etiologies, Management and Outcome: A Report from the SHOCK Trial Registry. J Am Coll Cardiol. 2000;36:1063-70.

455. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544-58.

456. Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1315-41.

457. Maack C, Eschenhagen T, Hamdani N, et al. Treatments targeting inotropy. Eur Heart J. 2019;40:3626-44.

458. Mebazaa A, Motiejunaite J, Gayat E, et al.; ESC Heart Failure Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology heart failure long-term registry. Eur J Heart Fail. 2018;20:332-41.

459. De Backer D, Biston P, Devriendt J, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-89.

460. Levy B, Clere-Jehl R, Legras A, et al. Collaborators. Epinephrine versus norepine-phrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018; 72:173-82.

461. Leopold V, Gayat E, Pirracchio R, et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med. 2018;44:847-56.

462. Hajjar LA, Teboul J. Mechanical Circulatory Support Devices for Cardiogenic Shock: State of the Art. Crit Care. 2019;23:76. doi:10.1186/s13054-019-2368-y.

463. Thiele H, Zeymer U, Neumann FJ, et al.; Investigators I-SIT. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287-96.

464. Thiele H, Zeymer U, Neumann FJ, et al., Intraaortic Balloon Pump in cardiogenic shock IIti. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638-45.

465. Unverzagt S, Buerke M, de Waha A, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev. 2015;3:CD007398.

466. Thiele H, Zeymer U, Thelemann N, et al.; Investigators IIT. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial. Circulation. 2019;139(3):395-403. doi:10.1161/CIRCULATIONAHA.118.038201.

467. Dumas F, Bougouin W, Geri G, et al. Emergency percutaneous coronary intervention in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011-8.

468. Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv. 2010;3:200-7. doi:10.1161/circinterventions.109.913665.

469. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med. 1997;336:1629-33. doi:10.1056/ nejm199706053362302.

470. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102:742-7. doi:10.1161/01.cir.102.7.742.

471. Miwa Y, Ikeda T, Mera H, et al. Effects of landiolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J. 2010;74:856-63. doi:10.1253/circj.cj09-0772.

472. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-ofhospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871-8. doi:10.1056/nejm199909163411203.

473. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol. 1996;27:67-75. doi:10.1016/0735-1097(95)00427-0.

474. Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.

475. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or animplantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.

476. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs Congestive Heart failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998;98:2574-9. doi:10.1161/01.cir.98.23.2574.

477. Hofmann R, Steinwender C, Kammler J, et al. Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. Wien Klin Wochenschr. 2004;116:744-9. doi:10.1007/s00508-004-0264-0.

478. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxincontrolled study. Eur Heart J. 1995;16:521-8. doi:10.1093/oxfordjournals.eurheartj.a060945.

479. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47-59.

480. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038-45. doi:10.1093/eurheartj/ehn579.

481. Batra G, Svennblad B, Held C, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016;102:926-33. doi:10.1136/ heartjnl-2015-308678.

482. Siu CW, Jim MH, Ho HH, et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest. 2007;132:44-9. doi:10.1378/chest.06-2733.

483. Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol. 1984;4:35-8. doi:10.1016/s0735-1097(84)80315-0.

484. Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation. 1999;41:47-55. doi:10.1016/s0300-9572(99)00032-5.

485. Misumida N, Ogunbayo GO, Kim SM, Abdel-Latif A. Frequency and significance of highdegree atrioventricular block and sinoatrial node dysfunction in patients with non-STelevation myocardial infarction. Am J Cardiol. 2018;122(10):1598-603.

486. Singh SM, FitzGerald G, Yan AT, et al. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. European Heart Journal. 2015;36:976-83. doi:10.1093/eurheartj/ehu357.

487. Damluji AA, van Diepen S, Katz JN, et al. Mechanical complications of acute myocardial infarction: a scientific statement from the American Heart Association. Circulation. 2021;144:e16-e35. doi:10.1161/cir.0000000000000985.

488. Matteucci M, Fina D, Jiritano F, et al. The use of extracorporeal membrane oxygenation in the setting of postinfarction mechanical complications: outcome analysis of the Extracorporeal Life Support Organization Registry. Interact Cardiovasc Thorac Surg. 2020;31:369-74. doi:10.1093/icvts/ivaa108.

489. Alerhand S, Adrian RJ, Long B, Avila J. Pericardial tamponade: A comprehensive emergency medicine and echocardiography review. Am J Emerg Med. 2022;58:159-74. doi:10.1016/j.ajem.2022.05.001.

490. Gong FF, Vaitenas I, Malaisrie SC, Maganti K. Mechanical complications of acute myocardial infarction: a review. JAMA Cardiol. 2021;6:341-9. doi:10.1001/jamacardio.2020. 3690.

491. Ronco D, Matteucci M, Ravaux JM, et al. Mechanical circulatory support as a bridge to definitive treatment in post-infarction ventricular septal rupture. JACC Cardiovasc Interv. 2021;14:1053-66. doi:10.1016/j.jcin.2021.02.046.

492. Kilic A, Sultan I, Chu D, et al. Mitral valve surgery for papillary muscle rupture: outcomes in 1342 patients from the society of thoracic surgeons database. Ann Thorac Surg. 2020;110:1975-81. doi:10.1016/j.athoracsur.2020.03.

493. Valle JA, Miyasaka RL, Carroll JD. Acute mitral regurgitation secondary to papillary muscle tear: is transcatheter edge-to-edge mitral valve repair a new paradigm? Circ Cardiovasc Interv. 2017;10:e005050. doi:10.1161/circinterventions.117.005050.

494. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36: 2921-64. doi:10.1093/eurheartj/ehv318.

495. Verma BR, Montane B, Chetrit M, et al. Pericarditis and post-cardiac injury syndrome as a sequelae of acute myocardial infarction. Curr Cardiol Rep. 2020;22:127. doi:10.1007/s11886-020-01371-5.

496. Weinsaft JW, Kim J, Medicherla CB, et al. Echocardiographic algorithm for postmyocardial infarction LV thrombus: a gatekeeper for thrombus evaluation by delayed enhancement CMR. JACC Cardiovasc Imaging. 2016;9:505-15. doi:10.1016/j.jcmg.2015.06.017.

497. Dalia T, Lahan S, Ranka S, et al. Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis. Thromb J. 2021;19:7. doi:10.1186/s12959-021-00259-w.

498. Dou Q, Wang W, Wang H, et al. Prognostic value of frailty in elderly patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Geriatr. 2019;19(1):222. doi:10.1186/s12877-019-1242-8.

499. Man C, Xiang S, Fan Y. Frailty for predicting all-cause mortality in elderly acute coronary syndrome patients: A meta-analysis. Ageing Res Rev. 2019;52:1-6. doi:10.1016/j.arr.2019.03.003.

500. Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J. 2011;32:1379-89. doi:10.1093/eurheartj/ehr033.

501. Tegn N, Abdelnoor M, Aaberge L, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016;387:1057-65. doi:10.1016/s0140-6736(15)01166-6.

502. Bueno H, Betriu A, Heras M, et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011;32:51-60. doi:10.1093/eurheartj/ehq375.

503. Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2019;4:846-54. doi:10.1001/jamacardio.2019.23.

504. Savonitto S, Ferri LA, Piatti L, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation. 2018;137:2435-45. doi:10.1161/circulationaha.117.032180.

505. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309. doi:10.1056/NEJMoa1205512.

506. Xu W, Cai Y, Liu H, et al. Frailty as a predictor of all-cause mortality and readmission in older patients with acute coronary syndrome: A systematic review and meta-analysis. Wien Klin Wochenschr. 2020;132(11-12):301-9. doi:10.1007/s00508-020-01650-9.

507. Damluji AA, Forman DE, Wang TY, et al.; American Heart Association Cardiovascular Disease in Older Populations Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Lifestyle and Cardiometabolic Health. Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association. Circulation. 2023;147(3):e32-e62. doi:10.1161/CIR.0000000000001112.

508. Richter D, Guasti L, Walker D, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of CardioOncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol. 2022;29:216-27. doi:10.1093/eurjpc/zwaa167.

509. Batty J, Qiu W, Gu S, et al. One-year clinical outcomes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: an analysis of the ICON1 study. Int J Cardiol. 2019;274:45-51. doi:10.1016/j.ijcard.2018.09.086.

510. Gu SZ, Beska B, Chan D, et al. Cognitive decline in older patients with non-ST elevation acute coronary syndrome. J Am Heart Assoc. 2019;8:e011218. doi:10.1161/jaha.118.011218.

511. Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2021;28(5):460-95. doi:10.1177/2047487320913379.

512. Salzwedel A, Jensen K, Rauch B, et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: update of the Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol. 2020;27:1756-74. doi:10.1177/2047487320905719.

513. Santiago de Araújo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of cardiac rehabilitation dose on mortality and morbidity: a systematic review and meta-regression analysis. Mayo Clin Proc. 2017;92:1644-59. doi:10.1016/j.mayocp.2017.07.019.

514. van Halewijn G, Deckers J, Tay HY, et al. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: a systematic review and meta-analysis. Int J Cardiol. 2017;232:294-303. doi:10.1016/j.ijcard.2016.12.125.

515. Aronov DM, Krasnitsky VB, Bubnova MG, et al. The effect of physical training on physical performance, hemodynamics, blood lipids, clinical course and prognosis in patients with coronary artery disease after acute coronary events during complex rehabilitation and secondary prevention at the outpatient stage (Russian cooperative study). Kardiologiia. 2009;(3):49-56. (In Russ.) Аронов Д. М., Красницкий В. Б., Бубнова М. Г. и др. Влияние физических тренировок на физическую работоспособность, гемодинамику, липиды крови, клиническое течение и прогноз у больных ишемической болезнью сердца после острых коронарных событий при комплексной реабилитации и вторичной профилактике на амбулаторно-поликлиническом этапе (Российское кооперативное исследование). Кардиология. 2009;(3):49-56.

516. Frederix I, Vanhees L, Dendale P, Goetschalckx K. A review of telerehabilitation for cardiac patients. J Telemed Telecare. 2015;21:45-53. doi:10.1177/1357633x14562732.

517. Thomas RJ, Beatty AL, Beckle TM, et al. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019;140:e69-e89. doi:10.1161/CIR.0000000000000663.

518. Anderson L, Sharp GA, Norton RJ, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2017;6:CD007130. doi:10.1002/14651858.CD007130.pub4.

519. Moulson N, Bewick D, Selway T, et al. Cardiac Rehabilitation During the COVID-19 Era: Guidance on Implementing Virtual Care. Can J Cardiol. 2020;36(8):1317-21. doi:10.1016/j.cjca.2020.06.006.

520. Abreu A, Frederix I, Dendale P, et al. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: the avenue towards EAPC accreditation programme: a position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2020;28:496-509. doi:10.1177/2047487320924912.

521. Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021;11:Cd001800. doi:10.1002/14651858.CD001800.pub4.

522. Ivanova GE, Melnikova EV, Shmonin AA, et al. Application of the international classification of functioning in the process of medical rehabilitation. Bulletin of Restorative Medicine. 2018;(6):2-77. (In Russ.) Иванова Г. Е., Мельникова Е. В., Шмонин А. А. и др.Применение международной классификации функционирования в процессе медицинской реабилитации. Вестник восстановительной медицины. 2018;(6):2-77.

523. Bubnova MG, Aronov DM. Cardiorehabilitation: stages, principles and international classification of functioning. Preventive medicine. 2020:23(5):40-9. (In Russ.) Бубнова М. Г., Аронов Д. М. Кардиореабилитация: этапы, принципы и международная классификация функционирования. Профилактическая медицина. 2020:23(5):40-9. doi:10.17116/profmed20202305140.

524. Guazzi M, Adams V, Conraads V, et al. European Association for Cardiovascular Prevention & Rehabilitation; American Heart Association. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126(18):2261-74. doi:10.1161/CIR.0b013e31826fb946.

525. Fletcher GF, Ades PA, Kligfield P, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8): 873-934. doi:10.1161/CIR.0b013e31829b5b44.

526. Long L, Anderson L, He J, et al. Exercise-based cardiac rehabilitation for stable angina: Systematic review and meta-analysis. Open Heart. 2019;6:e000989.

527. Fidalgo ASF, Farinatti P, Borges JP, et al. Institutional Guidelines for Resistance Exercise Training in Cardiovascular Disease: A Systematic Review. Sports Med. 2019;49:463-75.

528. Lawler PR, Filion KB, Eisenberg MJ. Efficacy of exercise-based cardiac rehabilitation postmyocardial infarction: A systematic review and meta-analysis of randomized controlled trials. Am Heart J. 2011;162:571-84.

529. Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. European Journal of Preventive Cardiology. 2013;20:442-67.

530. Аронов Д. М., Бубнова М. Г., Барбараш О. Л. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы: реабилитация и вторичная профилактика. Российский кардиологический журнал. 2015;(1):6-52. doi:10.15829/1560-4071-2015-1-6-52.

531. Бубнова М. Г., Аронов Д. М., Красницкий В. Б. и др. Программа домашних физических тренировок после острого коронарного синдрома и/или эндоваскулярного вмешательства на коронарных артериях: эффективность и проблема мотивации больных. Терапевтический Архив. 2014;86(1):23-32.

532. Hansen D, Bonné K, Alders T, et al. Exercise training intensity determination in cardiovascular rehabilitation: Should the guidelines be reconsidered? Eur J Prev Cardiol. 2019;26(18):1921-8. doi:10.1177/2047487319859450.

533. Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health. 1990;16(Suppl 1):55-8.

534. Hannan AL, Hing W, Simas V, et al. High-intensity interval training versus moderateintensity continuous training within cardiac rehabilitation: a systematic review and metaanalysis. Open Access J Sports Med. 2018;9:1-17. doi:10.2147/OAJSM.S150596.

535. Conraads VM, Pattyn N, De Maeyer C, et al. Aerobic interval training and continuous training equally improve aerobic exercise capacity in patients with coronary artery disease: the SAINTEX-CAD study. Int J Cardiol. 2015;179:203-10. doi:10.1016/j.ijcard.2014.10.155.

536. Pattyn N, Vanhees L, Cornelissen VA, et al. The long-term effects of a randomized trial comparing aerobic interval versus continuous training in coronary artery disease patients: 1-year data from the SAINTEX-CAD study. Eur J Prev Cardiol. 2016;23(11):1154-64. doi:10.1177/2047487316631200.

537. Sommaruga M, Angelino E, Della Porta P, et al. Best practice in psychological activities in cardiovascular prevention and rehabilitation: Position Paper. Monaldi Arch Chest Dis. 2018;88:966. doi:10.4081/monaldi.2018.966.

538. Pogosova N, Saner H, Pedersen SS, et al.; Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22(10):1290-306. doi:10.1177/2047487314543075.

539. Бойцов С. А., Погосова Н. В., Бадтиева В. А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. doi:10.15829/1560-4071-2023-5452.

540. Aldcroft SA, Taylor NF, Blackstock FC, O'Halloran PD. Psychoeducational rehabilitation for health behavior change in coronary artery disease: a systematic review of controlled trials. J Cardiopulm Rehabil Prev. 2011;31:273-81.

541. Tully PJ, Ang SY, Lee EJ, et al. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2021; 12(12):CD008012. doi:10.1002/14651858.CD008012.pub4.

542. Richards SH, Anderson L, Jenkinson CE, et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:247-59.

543. Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med. 2013;75:335-49.

544. Ambrosetti M, Abreu A, Cornelissen V, et al. Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. Eur J Prev Cardiol. 2021;28(5):541-57. doi:10.1093/eurjpc/zwaa080.

545. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484.

546. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86-97.

547. Thomson CC, Rigotti NA. Hospitaland clinic-based smoking cessation interventions for smokers with cardiovascular disease. Prog Cardiovasc Dis. 2003;45:459-79.

548. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ. 2004; 328(7446):977-80. doi:10.1136/bmj.38055.715683.55.

549. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.

550. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750-8.

551. Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2012;5:CD001837.

552. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.

553. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.

554. Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014;129:28-41.

555. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016;3: CD008286.

556. Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2019, Issue 4. Art. No.: CD013308. doi:10.1002/14651858.CD013308.

557. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:CD000146. doi:10.1002/14651858.CD000146.pub5.

558. Howes S, Hartmann-Boyce J, Livingstone-Banks J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020;4:CD000031. doi:10.1002/14651858. CD000031.pub5.

559. Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;2016:CD006103. doi:10.1002/14651858.CD006103.pub7.

560. Trichopoulou A, Bamia C, Norat T, et al. Modified Mediterranean diet and survival after myocardial infarction: the EPIC-Elderly STudy. Eur J Epidemiol. 2007;22:871-81.

561. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92:1189-96.

562. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonized meta-analysis. BMJ. 2019;366:l4570. doi:10.1136/ bmj.l4570.

563. Patterson R, McNamara E, Tainio M, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol. 2018;33:811-29. doi:10.1007/s10654018-0380-1.

564. Freeman AM, Morris PB, Barnard N, et al. Trending Cardiovascular Nutrition Controversies. J Am Coll Cardiol. 2017;69:1172-87.

565. Miller V, Mente A, Dehghan M, et al. Prospective Urban Rural Epidemiology study i. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet. 2017;390:2037-49.

566. Wood AM, Kaptoge S, Butterworth AS, et al.; Emerging Risk Factors Collaboration E-CVDUKBASG. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599912 current drinkers in 83 prospective studies. Lancet. 2018;39:1513-23.

567. Collaborators GBDA. Alcohol use and burden for 195 countries and territories, 19902016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392:1015-35.

568. Pack QR, Rodriguez-Escudero JP, Thomas RJ, et al. The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc. 2014;89:1368-77.

569. Jackson Ch L, Joshy G, Lewington S, et al. Body-mass index and all-cause mortality: individual participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388:776-86.

570. Khan SS, Ning H, Wilkins JT, et al. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol. 2018;3:280-7.

571. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399:1876-85. doi:10.1016/s01406736(22)00122-2.

572. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779-85. doi:10.1161/01.cir.99.6.779.

573. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e34. doi:10.1056/NEJMoa1800389.

574. Connor J, Hall W. Thresholds for safer alcohol use might need lowering. Lancet. 2018;391(10129):1460-1. doi:10.1016/S0140-6736(18)30545-2.

575. Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164. doi:10.1136/bmj.g4164.

576. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens. 2014;32:2285-95.

577. SPRINT Research Group, Wright JT, Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373: 2103-16.

578. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387: 957-67.

579. Pfeffer MA. ACE inhibitors in acute myocardial infarction: patient selection and timing. Circulation. 1998;97(22):2192-4. doi:10.1161/01.cir.97.22.2192.

580. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabetes Care. 2009;32:187-92.

581. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes — 2019. Diabetes Care Jan. 2019;42 (Supplement 1):S61-S70.

582. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2019. Diabetes Care Jan. 2019;42 (Supplement 1): S90-S102.

583. UK Prospective Diabetes Study (UKPDS) Group. Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.

584. Gurfinkel E, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J. 2004;25:25-31.

585. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD Study. Eur Heart J. 2008;29:1350-8. doi:10.1093/eurheartj/ehm581.

586. Clar C, Oseni Z, Flowers N, et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015(5):CD005050.

587. Caldeira D, Costa J, Vaz-Carneiro A. [Analysis of the Cochrane Review: Influenza Vaccines for Preventing Cardiovascular Disease. Cochrane Database Syst Rev. 2015;5:CD005050]. Acta Med Port. 2015;28:424-6.

588. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102:1953-6.

589. Caldeira D, Ferreira JJ, Costa J. Influenza vaccination and prevention of cardiovascular disease mortality. Lancet. 2018;391:426-7.

590. Fröbert O, Götberg M, Erlinge D, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation. 2021; 144:1476-84.

591. Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10:e019636. doi:10.1161/jaha.120.019636.

592. Fonseca HAR, Furtado RHM, Zimerman A, et al. Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial. Eur Heart J. 2022;43(41):4378-88. doi:10.1093/ eurheartj/ehac472.

593. Tardif JC, Kouz S, Waters DD, et al. Efficacy And safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497-505. doi:10.1056/NEJMoa1912388.

594. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838-47. doi:10.1056/NEJMoa2021372.

595. Thom S, Poulter N, Field J, et al.; UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918-29.

596. Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64:2071-82.

597. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387:967-77. doi:10.1056/NEJMoa2208275.

598. Astin F, Stephenson J, Probyn J, et al. Cardiologists' and patients' views about the informed consent process and their understanding of the anticipated treatment benefits of coronary angioplasty: a survey study. Eur J Cardiovasc Nurs. 2020;19:260-8. doi:10.1177/1474515119879050.

599. Scott JT, Thompson DR. Assessing the information needs of post-myocardial infarction patients: a systematic review. Patient Educ Couns. 2003;50:167-77. doi:10.1016/s07383991(02)00126-x.

600. Gherli R, Mariscalco G, Dalen M, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol. 2016;1:921-8.

601. Nijjer SS, Watson G, Athanasiou T, Malik IS. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a metaanalysis of 34 studies. Eur Heart J. 2011;32:2970-888.

602. Serebruany V, Bulaeva N, Golukhova E. Ticagrelor and heart surgery controversy: we may have better antiplatelet options. J Thorac Dis. 2016;8(11):3016-9. doi:10.21037/jtd.2016.11.26.

603. Qu J, Zhang D, Zhang H, et al. Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2022;163(3):1044-52.e15. doi:10.1016/j.jtcvs.2020.03.118.

604. Slater DK, Hlatky MA, Mark DB, et al. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. Am Journal Cardiol. 1987;60:766-70.

605. Lev EI, Battler A, Behar S, et al. Frequency, characteristics, and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns. American Journal Cardiol. 2003;91:224-7.

606. Gallo R, Steinhubl SR, White HD, et al.; STEEPLE Investigators. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial. Catheter Cardiovasc Interv. 2009;73(3):319-25. doi:10.1002/ccd.21764.

607. Montalescot G, White HD, Gallo R, et al.; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355(10):1006-17. doi:10.1056/NEJMoa052711.

608. Xu Y, Qiu Z, Yang R, et al. Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction. A metaanalysis of randomized controlled trials. Medicine. 2018;97:51(e13690). doi:10.1097/MD.0000000000013690.

609. Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. J Am Coll Cardiol. 2022;79(9):933-46. doi:10.1016/j.jacc.2022.01.018.

610. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-47. doi:10.1161/CIRCULATIONAHA.110.009449.